Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ASH 2025
Pharma
Why Lilly is betting on 2nd-line CLL despite 1st-line wins
Lilly is defying the typical earlier-is-better strategy of cancer drug commercialization.
Angus Liu
Dec 9, 2025 7:30am
ASH: J&J pressures CAR-T with Tecvayli combo in 2L myeloma
Dec 9, 2025 7:30am
ASH: Regeneron eyes simpler regimens to grow bispecifics' reach
Dec 8, 2025 8:00am
ASH: CSL proves 5-year durability of Hemgenix
Dec 7, 2025 12:00pm
ASH: Pfizer's Hympavzi reduces bleeding in hemophilia patients
Dec 6, 2025 4:00pm
J&J, Legend pull ASH paper comparing Carvykti to rival CAR-T
Nov 12, 2025 11:36am
